Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Dmitry Arbuck
Interventional psychiatry (Part 2)
While most psychiatric treatments have traditionally consisted of pharmacotherapy with oral medications, a better understanding of the pathophysiology underlying many mental illnesses has led to the recent increased use of treatments that require specialized administration and the creation of a subspecialty called interventional psychiatry. In Part 1 of this 2-part article (“Interventional psychiatry [Part 1]," Current Psychiatry, May 2023, p.
Interventional psychiatry (Part 1)
References 1. Vincent KM, Ryan M, Palmer E, et al. Interventional psychiatry. Postgrad Med. 2020;132(7):573-574. 2. Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1313-1321. 3. Kwentus J, Riesenberg RA, Marandi M, et al.
Neurotransmitter-based diagnosis and treatment: A hypothesis (Part 3)
References 1. Petroff OA. GABA and glutamate in the human brain. Neuroscientist. 2002;8(6):562-573. 2. Winkelman JW, Buxton OM, Jensen JE, et al. Reduced brain GABA in primary insomnia: preliminary data from 4T proton magnetic resonance spectroscopy (1H-MRS). Sleep. 2008;31(11):1499-1506. 3. Pereira AC, Mao X, Jiang CS, et al. Dorsolateral prefrontal cortex GABA deficit in older adults with sleep-disordered breathing. Proc Natl Acad Sci U S A. 2017;114(38):10250-10255. 4. Schür RR, Draisma LW, Wijnen JP, et al.
Neurotransmitter-based diagnosis and treatment: A hypothesis (Part 2)
References 1. Applyard SM, Hayward M, Young JI, et al. A role for the endogenous opioid beta-endorphin in energy homeostasis. Endocrinology. 2003;144(5):1753-1760. 2. Craft LL, Perna FM. The benefits of exercise for the clinically depressed. Prim Care Companion J Clin Psychiatry. 2004;6(3):104-111. 3. Dabo F, Nyberg F, Qin Zhou, et al. Plasma levels of beta-endorphin during pregnancy and use of labor analgesia. Reprod Sci. 2010;17(8):742-747. 4. Dunbar RI, Kaskatis K, MacDonald I, et al.
Could stem cells have a role in treating mental illnesses?
While laboratory studies move forward at full speed, the clinical use of stem cells—undifferentiated cells that can develop into many different types of specialized cells—remains controversial. Presently, only unadulterated stem cells are allowed to be used in patients, and only on an experimental and investigational basis. Stem cells that have been expanded, modified, or enhanced outside of the body are not allowed to be used for clinical application in the United States at this time.
A Fresh Look at Opioid Antagonists in Chronic Pain Management
A wide array of pharmacological tools and approaches may help patients overcome opioid deficiencies. As clinicians reduce their reliance on opioids for the treatment of pain, they are turning to a wider array of pharmacological tools and approaches to help overcome deficiencies of opioids, such as treatment-limiting side effects, and as aids in relieving difficult-to-treat pain conditions.1 One such approach is the use of opioid antagonists.
No Perfect Medicine-What You Need to Know About NSAIDs and Opioids
Your guide to safe use of NSAIDs and opioids, and possible drug-drug interactions. There are no perfect medications. This applies to both nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. A high level of mortality is associated with both NSAIDs and opioids.
Changes in patient behavior during COVID-19: What I’ve observed
Unprecedented circumstances, extraordinary times, continental shift, life-altering experience—the descriptions of the coronavirus disease 2019 (COVID-19) pandemic have been endless, and accurate. Every clinician who has cared for patients during these trying times has noticed new patterns in patient behavior.
Analgesics of the Future: Inside the Potential of 3 Drug Delivery Systems
A review of ZTlido (topical lidocaine), Zalviso and Dsuvia (sublingual sufentanil), and Wafermine (sublingual ketamine). By Jordan O'Leary, PharmD, Jayne Pawasauskas, PharmD, BCPS and Dmitry M. Arbuck, MD Pages 55-59 Overview For some patients, traditional oral or intravenous (IV) formulations may not be sufficient for pain control, come with undesirable adverse effects, or may not be clinically optimal. Therefore, alternative routes of delivery must be considered.
The Use of Antidepressants in Pain Management
The author shares clinical pearls for the use of these opioid alternatives in treating chronic pain and comorbid conditions. For more than two decades, chronic pain was delineated from acute pain if it continued beyond the expected healing period and persisted for 90 days or beyond.
Buprenorphine: A Promising Yet Overlooked Tool
A perspective on why partial agonists such as buprenorphine offer an effective alternative to full opioid agonists. Pages 33-38 Buprenorphine’s History and Availability Buprenorphine is one of the least understood opioids. It was unveiled in 1971 and became available for clinical use in Great Britain in 1978.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Dmitry
Contact Dmitry, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack